M
Marc Teitelbaum
Researcher at Leidos
Publications - 6
Citations - 207
Marc Teitelbaum is an academic researcher from Leidos. The author has contributed to research in topics: Medicine & Interquartile range. The author has an hindex of 2, co-authored 3 publications receiving 147 citations.
Papers
More filters
Journal ArticleDOI
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
J D Lundgren,Birgit Grund,Christina E. Barkauskas,Thomas L. Holland,Robert L. Gottlieb,Uriel Sandkovsky,Samuel M. Brown,Kirk U. Knowlton,Wesley H. Self,D. Clark Files,Mamta K Jain,T. Benfield,Michael E Bowdish,Bradley G Leshnower,Jason V. Baker,Jens-Ulrik Stæhr Jensen,Edward M. Gardner,Adit A. Ginde,Estelle S. Harris,Isik Somuncu Johansen,Norman Markowitz,Michael A. Matthay,Lars Østergaard,Christina C. Chang,Victoria J. Davey,Anna L. Goodman,Elizabeth S. Higgs,Elizabeth S. Higgs,Daniel D Murray,Thomas A. Murray,Roger Paredes,Mahesh K. B. Parmar,Andrew N. Phillips,Cavan S. Reilly,Shweta Sharma,Robin L. Dewar,Marc Teitelbaum,Deborah Wentworth,Huyen Cao,Paul Klekotka,Abdel Babiker,Annetine C. Gelijns,Virginia L. Kan,Virginia L. Kan,Mark N. Polizzotto,Mark N. Polizzotto,B. Taylor Thompson,H. Clifford Lane,James D. Neaton +48 more
TL;DR: In this paper, the effect of neutralizing monoclonal antibody (YL-CoV555) on patients with Coronavirus disease 2019 (Covid-19) was investigated.
Journal ArticleDOI
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Thomas L. Holland,Adit A. Ginde,Roger Paredes,Thomas A. Murray,Nicole W. Engen,Gregory A Grandits,Andrew M. Vekstein,Noel Ivey,Ahmad Mourad,Uriel Sandkovsky,Robert L. Gottlieb,Mezgebe Berhe,M. Jain,Rubria Marines-Price,Barbine Tchamba Agbor Agbor,Lourdes Mateu,Sergio España Cueto,Gemma Lladós,Eleftherios Mylonakis,Ralph Rogers,Fadi Shehadeh,Michael R. Fil,Kathryn A. Hibbert,Kami Kim,Thanh Tran,Peter E. Morris,Evan Cassity,Barbara W. Trautner,Lavannya Pandit,Kirk U. Knowlton,Lindsay M. Leither,Michael A. Matthay,Angela J. Rogers,Wonder P. Drake,Brooklyn Jones,Garyphallia Poulakou,Konstantinos N. Syrigos,Eduardo Fernández-Cruz,Marisa di Natale,Eyad Almasri,Leire Balerdi-Sarasola,Sanjay Bhagani,Katherine L. Boyle,Jonathan D Casey,Peter Chen,David J. Douin,D. Clark Files,Huldrych F. Günthard,R. Duncan Hite,Robert C. Hyzy,Akram Khan,M Kibirige,Robert Kidega,Ivan Kimuli,Francis Kiweewa,Jens-Ulrik Stæhr Jensen,Bradley G. Leshnower,Joseph Lutaakome,Prasad Manian,Vidya Menon,José Luis Morales-Rull,D. Shane O’Mahony,J Scott Overcash,Srikanth Ramachandruni,Jay S. Steingrub,Hassan S. Taha,Michael F. Waters,Barnaby Edward Young,Andrew N. Phillips,Daniel D Murray,Tomas Ostergaard Jensen,M. L. Padilla,David Sahner,Katy Shaw-Saliba,Robin Dewar,Marc Teitelbaum,Ven Natarajan,Muhammad T Rehman,Sarah Pett,Fleur Hudson,Giota Touloumi,Samuel M. Brown,Wesley H. Self,Christina C. Chang,Adriana Sanchez,Amy C. Weintrob,Timothy Hatlen,Birgit Grund,Shweta Sharma,Cavan S. Reilly,Pedro Garbes,Mark T. Esser,A. Templeton,Abdel Babiker,Victoria J. Davey,Annetine C. Gelijns,Elizabeth S. Higgs,V. Kan,Gail V. Matthews,B. Taylor Thompson,James D. Neaton,H. Clifford Lane,Jens D Lundgren +102 more
TL;DR: Among patients hospitalised with COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve the primary outcome of time to sustained recovery but was safe and mortality was lower.
Posted ContentDOI
Design and implementation of the multi-arm, multi-stage Therapeutics for Inpatients with COVID-19 (TICO) platform master protocol: An Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.
Daniel D Murray,Abdel Babiker,Jason V. Baker,Christina E. Barkauskas,Samuel M. Brown,Samuel M. Brown,Christina C. Chang,Victoria J. Davey,Annetine C. Gelijns,Adit A. Ginde,Birgit Grund,Elizabeth S. Higgs,Fleur Hudson,Virginia K Kan,Virginia K Kan,H. Clifford Lane,Thomas A. Murray,Roger Paredes,Mahesh K. B. Parmar,Sarah Pett,Andrew N. Phillips,Mark N. Polizzotto,Mark N. Polizzotto,Cavan S. Reilly,Uriel Sandkovsky,Shweta Sharma,Marc Teitelbaum,B. Taylor Thompson,Barnaby Edward Young,Barnaby Edward Young,James D. Neaton,Jens D Lundgren +31 more
TL;DR: The TICO MAMS platform trial has been implemented efficiently across a global network of sites and several trial networks and will generate results rapidly for multiple novel neutralizing monoclonal antibodies and other therapeutics agents.
Journal ArticleDOI
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).
Daniel D Murray,Abdel Babiker,Jason V. Baker,Christina E. Barkauskas,Samuel M. Brown,Samuel M. Brown,Christina C. Chang,Victoria J. Davey,Annetine C. Gelijns,Adit A. Ginde,Birgit Grund,Elizabeth S. Higgs,Fleur Hudson,Virginia L. Kan,Virginia L. Kan,H. Clifford Lane,Thomas A. Murray,Roger Paredes,Mahesh K. B. Parmar,Sarah Pett,Andrew N. Phillips,Mark N. Polizzotto,Mark N. Polizzotto,Cavan S. Reilly,Uriel Sandkovsky,Shweta Sharma,Marc Teitelbaum,B. Taylor Thompson,Barnaby Edward Young,Barnaby Edward Young,James D. Neaton,Jens D Lundgren +31 more
TL;DR: The Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership as discussed by the authors aims to provide safe and effective therapies for COVID19 patients by developing and testing new therapies.
Journal ArticleDOI
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
Christina E. Barkauskas,Eleftherios Mylonakis,Garyphallia Poulakou,Barnaby Edward Young,David M. Vock,Lianne Siegel,Nicole W. Engen,Gregory A Grandits,N. Mosaly,Andrew M. Vekstein,Ralph Rogers,Fadi Shehadeh,Matthew Kaczynski,Evangelia K. Mylona,Konstantinos N. Syrigos,Vasiliki Rapti,David C. Lye,Shiau Hui Diong,Lindsay M. Leither,Kirk U. Knowlton,Mamta K. Jain,Rubria Marines-Price,Alice Osuji,J Scott Overcash,Ioannis Kalomenidis,Zafeiria Barmparessou,Michael F. Waters,Karla P. Zepeda,Peter Chen,S H Vahdat Torbati,Francis Kiweewa,Nicholus Sebudde,Eyad Almasri,Alyssa Hughes,Sanjay Bhagani,Alison Rodger,Uriel Sandkovsky,Robert L. Gottlieb,Eriobu Nnakelu,Barbara W. Trautner,Vidya Menon,Joseph Lutaakome,Michael A. Matthay,Philip Robinson,Konstantinos Protopapas,Nikolaos Koulouris,Ivan Kimuli,Amiran Baduashvili,Dominique L Braun,Huldrych F. Günthard,Srikanth Ramachandruni,Robert Kidega,Kamila Kim,Timothy Hatlen,Andrew N. Phillips,Daniel D Murray,Tomas Ostergaard Jensen,Maria Padilla,Evan X. Accardi,Katy Shaw-Saliba,Robin Dewar,Marc Teitelbaum,Ven Natarajan,Sylvain Laverdure,Helene C. Highbarger,Muhammad T Rehman,S Vogel,D. Vallee,Page E. Crew,Negin Atri,Adam Schechner,Sarah Pett,Fleur Hudson,Jonathan Badrock,Giota Touloumi,Samuel M. Brown,Wesley H. Self,Crystal M. North,Adit A. Ginde,Christina C. Chang,Anthony D. Kelleher,Stephanie Nagy-Agren,S. M. Vasudeva,D.C. Looney,H. H. Nguyen,Adriana Sanchez,Amy C. Weintrob,Birgit Grund,Shweta Sharma,Cavan S. Reilly,Roger Paredes,Agnieszka J. Bednarska,Norman P. Gerry,Abdel Babiker,Victoria J. Davey,Annetine C. Gelijns,Elizabeth S. Higgs,V. Kan,Gail V. Matthews,B. Taylor Thompson,Philippe Legenne,Richa Chandra,H. Clifford Lane,James D. Neaton,Jens D Lundgren +104 more
TL;DR: It is highlighted that effective antiviral therapies for patients hospitalized with COVID-19 remain an unmet need and important lessons regarding how to conduct such trials and test promising compounds can be gleaned from this study.